Emergent BioSolutions

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.6K

Market Cap: -

Website

Introduction: Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units ...

Clinical Trials

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

Phase 1

Completed

Conditions: Smallpox

Interventions: Drug: Brincidofovir

First Posted Date: 2023-07-07

Last Posted Date: 2024-05-01

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 44

Registration Number: NCT05935917

Locations: 🇺🇸
Altasciences, Overland Park, Kansas, United States

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Phase 1

Completed

Conditions: Opioid Overdose

Interventions: Combination Product: 16 mg naloxone AP003
Combination Product: 8 mg naloxone NARCAN Nasal Spray

First Posted Date: 2022-05-17

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 24

Registration Number: NCT05377255

Locations: 🇺🇸
Syneos Health Clinical Research Services, Miami, Florida, United States

Study of SIAN Nasal Spray in Healthy Adults

Phase 1

Completed

Conditions: Cyanide Poisoning

Interventions: Drug: Stabilized Isoamyl Nitrite (SIAN)

First Posted Date: 2022-01-18

Last Posted Date: 2024-04-29

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 47

Registration Number: NCT05194358

Locations: 🇺🇸
Austin Clinical Research Unit - PPD Phase I Clinic, Austin, Texas, United States
🇺🇸
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

Universal Influenza A Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Human Influenza

Interventions: Biological: UFluA 20 µg each antigen/dose
Biological: UFluA 60 µg each antigen/dose
Biological: Placebo

First Posted Date: 2021-12-13

Last Posted Date: 2024-06-13

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 27

Registration Number: NCT05155319

Locations: 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults

Phase 1

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Biological: COVID-HIG

First Posted Date: 2021-12-02

Last Posted Date: 2024-06-20

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 23

Registration Number: NCT05142306

Locations: 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸
Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: COVID-HIGIV
Other: Placebo (saline)

First Posted Date: 2020-12-10

Last Posted Date: 2024-03-21

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 28

Registration Number: NCT04661839

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Phase 2

Completed

Conditions: Anthrax

Interventions: Drug: Doxycycline 100Mg Tablet
Drug: Ciprofloxacin 500Mg Tablet
Biological: AV7909

First Posted Date: 2019-08-26

Last Posted Date: 2024-03-21

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 210

Registration Number: NCT04067011

Locations: 🇺🇸
Meridian Clinical Research, LLC, Omaha, Nebraska, United States
🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States

and more 1 locations

VELOCITY: An Anthrax Vaccine Clinical Study

Phase 3

Completed

Conditions: Anthrax

Interventions: Biological: AV7909
Biological: BioThrax

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 3862

Registration Number: NCT03877926

Locations: 🇺🇸
Clinical Research Consortium, an AMR company, Tempe, Arizona, United States
🇺🇸
New Horizon Research Center, Inc, Miami, Florida, United States
🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States

and more 25 locations

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Phase 1

Completed

Conditions: Zika Virus Infection
Zika Virus Disease

Interventions: Biological: Zika Virus Immune Globulin (ZIKV-IG)
Other: Placebo

First Posted Date: 2018-08-10

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 30

Registration Number: NCT03624946

Locations: 🇨🇦
Syneos Health, Early Phase, Toronto, Ontario, Canada

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not yet recruiting

Conditions: Anthrax

Interventions: Drug: AIGIV

First Posted Date: 2018-06-26

Last Posted Date: 2024-02-15

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 10

Registration Number: NCT03569514

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy